All In Biotech

Drug Trial Radar · NCT06039579

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Phase 2a Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Orally Administered Investigational Capsid Inhibitor Monotherapy in HIV-1 Infected Treatment-Naïve Adults

Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Oct 25, 2023

Primary completion

Jun 24, 2024

Study completion Jun 24, 2024

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Sep 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.

Conditions

  • HIV Infections

Interventions

  • VH4004280Drug

    VH4004280 was administered as tablets orally at Day 1.

  • VH4011499Drug

    VH4011499 was administered as tablets orally at Day 1 and Day 6.

  • VH4004280 Matching PlaceboDrug

    VH4004280 Matching Placebo was administered as tablets orally at Day 1.

  • VH4011499 Matching PlaceboDrug

    VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.

  • Antiretroviral therapyDrug

    Antiretroviral therapy was administered as available and as per investigator's recommendation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10Time frame: From Baseline (Day 1) and up to Day 11
  2. Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10Time frame: From Baseline (Day 1) and up to Day 11

Locations

20 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Newark, New Jersey

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, Argentina

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Nantes, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Cologne, Germany

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Guadalajara, Mexico

  • GSK Investigational Site

    Mexico City, Mexico

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.